Current progress in the development of prophylactic and therapeutic vaccines

被引:23
作者
Li, Tingting [1 ,2 ,3 ]
Qian, Ciying [1 ,2 ,3 ]
Gu, Ying [1 ,2 ,3 ]
Zhang, Jun [1 ,2 ,3 ]
Li, Shaowei [1 ,2 ,3 ]
Xia, Ningshao [1 ,2 ,3 ,4 ]
机构
[1] Xiamen Univ, Sch Life Sci, Sch Publ Hlth, State Key Lab Mol Vaccinol & Mol Diagnost, Xiamen 361102, Peoples R China
[2] Xiamen Univ, Natl Inst Diagnost & Vaccine Dev Infect Dis, Xiamen 361102, Peoples R China
[3] Xiang An Biomed Lab, Xiamen 361102, Peoples R China
[4] Chinese Acad Med Sci, Res Unit Frontier Technol Struct Vaccinol, Xiamen 361102, Peoples R China
基金
中国国家自然科学基金;
关键词
prophylactic vaccine; therapeutic vaccine; immune response; infectious diseases; cancers; chronic diseases; CELL LUNG-CANCER; CANDIDATE BIOCONJUGATE VACCINE; HIGH BLOOD-PRESSURE; PHASE-II TRIAL; BREAST-CANCER; B-CELL; CLINICAL-TRIAL; MESSENGER-RNA; COLON-CANCER; DOUBLE-BLIND;
D O I
10.1007/s11427-022-2230-4
中图分类号
Q [生物科学];
学科分类号
07 ; 0710 ; 09 ;
摘要
Vaccines are essential public health tools and play an important role in reducing the burden of infectious diseases in the population. Emerging infectious diseases and outbreaks pose new challenges for vaccine development, requiring the rapid design and production of safe and effective vaccines against diseases with limited resources. Here, we focus on the development of vaccines in broad fields ranging from conventional prophylactic vaccines against infectious diseases to therapeutic vaccines against chronic diseases and cancer providing a comprehensive overview of recent advances in eight different vaccine forms (live attenuated vaccines, inactivated vaccines, polysaccharide and polysaccharide conjugate vaccines, recombinant subunit vaccines, virus-like particle and nanoparticle vaccines, polypeptide vaccines, DNA vaccines, and mRNA vaccines) and the therapeutic vaccines against five solid tumors (lung cancer breast cancer colorectal cancer liver cancer and gastric cancer), three infectious diseases (human immunodeficiency virus, hepatitis B virus and human papillomavirus-induced diseases) and three common chronic diseases (hypertension, diabetes mellitus and dyslipidemia). We aim to provide new insights into vaccine technologies, platforms, applications and understanding of potential next-generation preventive and therapeutic vaccine technologies paving the way for the vaccines design in the future.
引用
收藏
页码:679 / 710
页数:32
相关论文
共 193 条
  • [21] Personalized neoantigen vaccine prevents postoperative recurrence in hepatocellular carcinoma patients with vascular invasion
    Cai, Zhixiong
    Su, Xiaoping
    Qiu, Liman
    Li, Zhenli
    Li, Xiaolou
    Dong, Xiuqing
    Wei, Fuqun
    Zhou, Yang
    Luo, Liuping
    Chen, Geng
    Chen, Hengkai
    Wang, Yingchao
    Zeng, Yongyi
    Liu, Xiaolong
    [J]. MOLECULAR CANCER, 2021, 20 (01)
  • [22] Results of the First Phase 1 Clinical Trial of the HER-2/neu Peptide (GP2) Vaccine in Disease-Free Breast Cancer Patients
    Carmichael, Mark G.
    Benavides, Linda C.
    Holmes, Jarrod P.
    Gates, Jeremy D.
    Mittendorf, Elizabeth A.
    Ponniah, Sathibalan
    Peoples, George E.
    [J]. CANCER, 2010, 116 (02) : 292 - 301
  • [23] Development of an Interleukin-1β Vaccine in Patients with Type 2 Diabetes
    Cavelti-Weder, Claudia
    Timper, Katharina
    Seelig, Eleonora
    Keller, Cornelia
    Osranek, Martin
    Lassing, Ute
    Spohn, Gunther
    Maurer, Patrik
    Mueller, Philipp
    Jennings, Gary T.
    Willers, Joerg
    Saudan, Philippe
    Donath, Marc Y.
    Bachmann, Martin F.
    [J]. MOLECULAR THERAPY, 2016, 24 (05) : 1003 - 1012
  • [24] Virosome-Formulated Plasmodium falciparum AMA-1 & CSP Derived Peptides as Malaria Vaccine: Randomized Phase 1b Trial in Semi-Immune Adults & Children
    Cech, Patrick Georges
    Aebi, Thomas
    Abdallah, Mwanajaa Shomari
    Mpina, Maxmillian
    Machunda, Ester Barnabas
    Westerfeld, Nicole
    Stoffel, Sabine Alexandra
    Zurbriggen, Rinaldo
    Pluschke, Gerd
    Tanner, Marcel
    Daubenberger, Claudia
    Genton, Blaise
    Abdulla, Salim
    [J]. PLOS ONE, 2011, 6 (07):
  • [25] Safety and immunogenicity of the SARS-CoV-2 ARCoV mRNA vaccine in Chinese adults: a randomised, double-blind, placebo-controlled, phase 1 trial
    Chen, Gui-Ling
    Li, Xiao-Feng
    Dai, Xia-Hong
    Li, Nan
    Cheng, Meng-Li
    Huang, Zhen
    Shen, Jian
    Ge, Yu-Hua
    Shen, Zhen-Wei
    Deng, Yong-Qiang
    Yang, Shu-Yuan
    Zhao, Hui
    Zhang, Na-Na
    Zhang, Yi-Fei
    Wei, Ling
    Wu, Kai-Qi
    Zhu, Meng-Fei
    Peng, Cong-Gao
    Jiang, Qi
    Cao, Shou-Chun
    Li, Yu-Hua
    Zhao, Dan-Hua
    Wu, Xiao-Hong
    Ni, Ling
    Shen, Hua-Hao
    Dong, Chen
    Ying, Bo
    Sheng, Guo-Ping
    Qin, Cheng-Feng
    Gao, Hai-Nv
    Li, Lan-Juan
    [J]. LANCET MICROBE, 2022, 3 (03): : E193 - E202
  • [26] RNA Sensors of the Innate Immune System and Their Detection of Pathogens
    Chen, Nanhua
    Xia, Pengpeng
    Li, Shuangjie
    Zhang, Tangjie
    Wang, Tony T.
    Zhu, Jianzhong
    [J]. IUBMB LIFE, 2017, 69 (05) : 297 - 304
  • [27] Enhanced Cross-Reactive and Polyfunctional Effector-Memory T Cell Responses by ICVAX-a Human PD1-Based Bivalent HIV-1 Gag-p41 Mosaic DNA Vaccine
    Chen, Samantha M. Y.
    Wong, Yik Chun
    Yim, Lok Yan
    Zhang, Haoji
    Wang, Hui
    Lui, Grace Chung Yan
    Li, Xin
    Tang, Xian
    Cheng, Lin
    Du, Yanhua
    Peng, Qiaoli
    Wang, Jinlin
    Kwok, Hau-Yee
    Huang, Haode
    Lau, Thomas Tsz-Kan
    Chan, Denise Pui Chung
    Wong, Bonnie Chun Kwan
    Liu, Li
    Chakrabarti, Lisa A.
    Lee, Shui Shan
    Chen, Zhiwei
    [J]. JOURNAL OF VIROLOGY, 2022, 96 (07)
  • [28] A Phase II, Prospective, Randomized, Multicenter, Open-Label Study of GX-188E, an HPV DNA Vaccine, in Patients with Cervical Intraepithelial Neoplasia 3
    Choi, Youn Jin
    Hur, Soo Young
    Kim, Tae-Jin
    Hong, Sung Ran
    Lee, Jae Kwan
    Cho, Chi-Heum
    Park, Ki Seok
    Woo, Jung Won
    Sung, Young Chul
    Suh, You Suk
    Park, Jong Sup
    [J]. CLINICAL CANCER RESEARCH, 2020, 26 (07) : 1616 - 1623
  • [29] Results of a Randomized Phase IIb Trial of Nelipepimut-S thorn Trastuzumab versus Trastuzumab to Prevent Recurrences in Patients with High-Risk HER2 Low-Expressing Breast Cancer
    Clifton, G. Travis
    Hale, Diane
    Vreeland, Timothy J.
    Hickerson, Annelies T.
    Litton, Jennifer K.
    Alatrash, Gheath
    Murthy, Rashmi K.
    Qiao, Na
    Philips, Anne V.
    Lukas, Jason J.
    Holmes, Jarrod P.
    Peoples, George E.
    Mittendorf, Elizabeth A.
    [J]. CLINICAL CANCER RESEARCH, 2020, 26 (11) : 2515 - 2523
  • [30] The development and use of the E75 (HER2 369-377) peptide vaccine
    Clifton, Guy T.
    Peoples, George E.
    Mittendorf, Elizabeth A.
    [J]. FUTURE ONCOLOGY, 2016, 12 (11) : 1321 - 1329